TCTMD

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

Inclisiran (Leqvio) may now be used as a first-line treatment option for patients with high cholesterol levels, according to an announcement from drugmaker Novartis. The US Food and Drug ...
TCTMD

Inclisiran Effective as Monotherapy for Lower-Risk Primary Prevention

For low-risk patients not currently taking any lipid-lowering therapy, the use of inclisiran (Leqvio; Novartis) alone safely and effectively cuts LDL-cholesterol levels, the randomized VICTORION-Mono ...
Hosted on MSN

Early and sustained LDL-C goal achieved with inclisiran in patients at high cardiovascular risk

More patients with hypercholesterolemia at high/very high risk of cardiovascular (CV) events achieved low-density lipoprotein cholesterol (LDL-C) goals with inclisiran compared with placebo, when ...
News Medical

Inclisiran helps more high-risk patients reach LDL cholesterol goals compared to standard therapy

More patients with hypercholesterolemia at high/very high risk of cardiovascular (CV) events achieved low-density lipoprotein cholesterol (LDL-C) goals with inclisiran compared with placebo, when ...